# Cardiol Therapeutics Inc.: financial statements, quarterly

CRDL · Nasdaq · CIK 1702123 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/crdl.md) · [Financials](/companies/crdl/financials.md) · [Filings](/companies/crdl/filings.md) · [Insiders](/companies/crdl/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/crdl/financials.md?period=annual).

## Balance sheet

| Line item | Unit | period not labelled (2019-12-31) | period not labelled (2020-12-31) | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [7.0](/filings/0001104659-23-037820.md) | [14.0](/filings/0001104659-24-041952.md) | [83.9](/filings/0001104659-24-041952.md) | [59.5](/filings/0001410578-25-000588.md) | [34.9](/filings/0001104659-26-037844.md) | [30.6](/filings/0001104659-26-037844.md) | [21.4](/filings/0001104659-26-037844.md) |
| Current assets | $m | not reported | [14.9](/filings/0001104659-22-047891.md) | [87.1](/filings/0001104659-23-037820.md) | [61.4](/filings/0001104659-24-041952.md) | [36.2](/filings/0001410578-25-000588.md) | [31.7](/filings/0001104659-26-037844.md) | [23.5](/filings/0001104659-26-037844.md) |
| Total assets | $m | not reported | [15.9](/filings/0001104659-22-047891.md) | [87.9](/filings/0001104659-23-037820.md) | [62.0](/filings/0001104659-24-041952.md) | [36.7](/filings/0001410578-25-000588.md) | [31.9](/filings/0001104659-26-037844.md) | [23.6](/filings/0001104659-26-037844.md) |
| Current liabilities | $m | not reported | [2.5](/filings/0001104659-22-047891.md) | [11.6](/filings/0001104659-23-037820.md) | [9.8](/filings/0001104659-24-041952.md) | [8.3](/filings/0001410578-25-000588.md) | [7.0](/filings/0001104659-26-037844.md) | [5.7](/filings/0001104659-26-037844.md) |
| Total liabilities | $m | not reported | [2.6](/filings/0001104659-22-047891.md) | [11.6](/filings/0001104659-23-037820.md) | [9.8](/filings/0001104659-24-041952.md) | [8.5](/filings/0001410578-25-000588.md) | [7.1](/filings/0001104659-26-037844.md) | [5.7](/filings/0001104659-26-037844.md) |
| Shareholders' equity | $m | [14.7](/filings/0001104659-23-037820.md) | [13.3](/filings/0001104659-24-041952.md) | [76.2](/filings/0001104659-24-041952.md) | [52.2](/filings/0001410578-25-000588.md) | [28.2](/filings/0001104659-26-037844.md) | [24.7](/filings/0001104659-26-037844.md) | [17.9](/filings/0001104659-26-037844.md) |

- Cash and equivalents: ifrs-full:CashAndCashEquivalents
- Current assets: ifrs-full:CurrentAssets
- Total assets: ifrs-full:Assets
- Current liabilities: ifrs-full:CurrentLiabilities
- Total liabilities: ifrs-full:Liabilities
- Shareholders' equity: ifrs-full:Equity

Shares outstanding: 100,257,009 at 2025-12-31, from the cover of the [40-F filed 2026-03-31](/filings/0001104659-26-037844.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.